Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Bayer AG A life science firm providing pharmaceuticals, consumer health, and crop science solutions.	Germany	BAY
Beam Therapeutics Inc. Developing precision genetic medicines using base editing to provide cures for serious diseases.	United States of America	BEAM
BELITE BIO, INC Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.	United States of America	BLTE
Benchmark Holdings Plc Aquaculture biotech providing nutrition and health solutions for sustainable farming.	United Kingdom	BMK
Benitec Biopharma Inc. Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.	United States of America	BNTC
BeOne Medicines Ltd. Develops innovative and accessible cancer treatments for patients worldwide.	United States of America	ONC
BGM Group Ltd. A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.	United States of America	BGM
Bicara Therapeutics Inc. Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.	United States of America	BCAX
BICYCLE THERAPEUTICS PLC Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.	United States of America	BCYC
BIFIDO. Co. Ltd Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.	South Korea	238200